Literature DB >> 19430847

Correlating metabolic activity with cellular proliferation in follicular lymphomas.

Bingfeng Tang1, Jozef Malysz, Vonda Douglas-Nikitin, Richard Zekman, Regina Heather Wong, Ishmael Jaiyesimi, Ching-Yee Oliver Wong.   

Abstract

PURPOSE: The aim of this study was to correlate metabolic behavior of follicular lymphoma with proliferative index (Ki67).
MATERIALS AND METHODS: Pre-treatment 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography-computed tomography scans of 23 patients with pathologic diagnosis of follicular lymphoma were retrospectively analyzed together with Ki67. The maximal standardized uptake value (SUV) was measured and corrected to glucose level of 100 mg/dl over the biopsy region (BxSUV100) and at the highest tumor activity of the body (BmSUV100).
RESULTS: BxSUV100 was significantly correlated with Ki67 (p = 0.037). There was an increasing trend of metabolic activity across the pathologic grades of follicular lymphomas. BmSUV100 and BxSUV100 were also significantly different (p < 0.0005), suggesting potential pitfalls of sampling error by histology.
CONCLUSION: The increasing trend of metabolic activity across follicular lymphoma grades correlates with cellular proliferation. The metabolic information from positron emission tomography-computed tomography may offer another useful parameter in the management of follicular lymphomas.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19430847     DOI: 10.1007/s11307-009-0226-z

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  13 in total

1.  Ki67 staining pattern as a diagnostic tool in the evaluation of lymphoproliferative disorders.

Authors:  R J Bryant; P M Banks; D P O'Malley
Journal:  Histopathology       Date:  2006-04       Impact factor: 5.087

2.  Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas.

Authors:  Maroun Karam; Leon Novak; Jomol Cyriac; Ameera Ali; Tipu Nazeer; Francis Nugent
Journal:  Cancer       Date:  2006-07-01       Impact factor: 6.860

3.  Glucose-normalized standardized uptake value from (18)F-FDG PET in classifying lymphomas.

Authors:  Ching-Yee Oliver Wong; Joseph Thie; Kelly J Parling-Lynch; Dana Zakalik; Jeffrey H Margolis; Marianne Gaskill; Jack Hill; Feng Qing; Darlene Fink-Bennett; Conrad Nagle
Journal:  J Nucl Med       Date:  2005-10       Impact factor: 10.057

Review 4.  Staging and classification of lymphoma.

Authors:  Ping Lu
Journal:  Semin Nucl Med       Date:  2005-07       Impact factor: 4.446

5.  Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation.

Authors:  J Gerdes; U Schwab; H Lemke; H Stein
Journal:  Int J Cancer       Date:  1983-01-15       Impact factor: 7.396

6.  Comparison between 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma.

Authors:  Martin Allen-Auerbach; Andrew Quon; Wolfgang A Weber; Sebastian Obrzut; Tyler Crawford; Daniel H S Silverman; Osman Ratib; Michael E Phelps; Johannes Czernin
Journal:  Mol Imaging Biol       Date:  2004 Nov-Dec       Impact factor: 3.488

Review 7.  Utility of fluorodeoxyglucose-PET imaging in the management of patients with Hodgkin's and non-Hodgkin's lymphomas.

Authors:  Rakesh Kumar; Ivan Maillard; Stephen J Schuster; Abass Alavi
Journal:  Radiol Clin North Am       Date:  2004-11       Impact factor: 2.303

8.  Impact of [18f] fluorodeoxyglucose positron emission tomography on staging and management of early-stage follicular non-hodgkin lymphoma.

Authors:  Andrew Wirth; Marcus Foo; John F Seymour; Michael P Macmanus; Rodney J Hicks
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-03-04       Impact factor: 7.038

Review 9.  The role of PET imaging in lymphoma.

Authors:  Catherine Burton; Peter Ell; David Linch
Journal:  Br J Haematol       Date:  2004-09       Impact factor: 6.998

10.  18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading.

Authors:  S Wöhrer; U Jaeger; K Kletter; A Becherer; A Hauswirth; K Turetschek; M Raderer; M Hoffmann
Journal:  Ann Oncol       Date:  2006-02-23       Impact factor: 32.976

View more
  6 in total

1.  Bio-effect model applied to 131I radioimmunotherapy of refractory non-Hodgkin's lymphoma.

Authors:  Peter L Roberson; Hanan Amro; Scott J Wilderman; Anca M Avram; Mark S Kaminski; Matthew J Schipper; Yuni K Dewaraja
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-12-21       Impact factor: 9.236

2.  Patterns of use and survival outcomes of positron emission tomography for initial staging in elderly follicular lymphoma patients.

Authors:  Ashish Rai; Loretta J Nastoupil; Jessica N Williams; Joseph Lipscomb; Kevin C Ward; David H Howard; Daniel Lee; Christopher R Flowers
Journal:  Leuk Lymphoma       Date:  2016-11-10

3.  FDG-PET in Follicular Lymphoma Management.

Authors:  C Bodet-Milin; T Eugène; T Gastinne; E Frampas; S Le Gouill; F Kraeber-Bodéré
Journal:  J Oncol       Date:  2012-07-30       Impact factor: 4.375

4.  Correlation between the Uptake of 18F-Fluorodeoxyglucose (18F-FDG) and the Expression of Proliferation-Associated Antigen Ki-67 in Cancer Patients: A Meta-Analysis.

Authors:  Sheng-Ming Deng; Wei Zhang; Bin Zhang; Yin-Yin Chen; Ji-Hui Li; Yi-Wei Wu
Journal:  PLoS One       Date:  2015-06-03       Impact factor: 3.240

5.  Correlations between functional imaging markers derived from PET/CT and diffusion-weighted MRI in diffuse large B-cell lymphoma and follicular lymphoma.

Authors:  Xingchen Wu; Hannu Pertovaara; Pasi Korkola; Prasun Dastidar; Ritva Järvenpää; Hannu Eskola; Pirkko-Liisa Kellokumpu-Lehtinen
Journal:  PLoS One       Date:  2014-01-15       Impact factor: 3.240

6.  Correlations between the Maximum Standard Uptake Value of Positron Emission Tomography/Computed Tomography and Laboratory Parameters before and after Treatment in Patients with Lymphoma.

Authors:  Edip Ucar; Hulya Yalcin; Gamze Hande Kavvasoglu; Gul Ilhan
Journal:  Chin Med J (Engl)       Date:  2018-08-05       Impact factor: 2.628

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.